Yu-Wen Chen MD, Presenter: Nothing to Disclose

Ming-Feng Hou MD, Abstract Co-Author: Nothing to Disclose

Fu O-Yang MD, Abstract Co-Author: Nothing to Disclose

Gin-Chung Liu MD, Abstract Co-Author: Nothing to Disclose

In here, we will discuss the correlation of FDG PET/CT finding for the breast cancer patients whose serum level of tumor marker is increased during follow-up.

During the six-month period, consecutively 27 patients had the indication of increased serum level of tumor marker, CEA or CA153 or both recieved FDG PET/CT diagnosis under suspion of recurrence. The mean age is 55.8 year-old (from 36 to 70 year-old). The initial stage of breast cancer with infiltrating ductal carcinoma major,is stage II, except two cases as stage III. Two of patients have bilateral breast cancer. The follow-up duration before FDG PET/CT procedure is from 6 to 240 months. All of them received dual phase protocol of FDG PET/CT study (GE, 16 DST). After imaging diagnosis, at least six-month period was follow-up in clinic.

21 of enrolled patients have elevation of CEA serum level only. 3 patients have elevation of serum level of CA153 only. And the other 3 patients have increased both CEA/CA153 serum level. Extensively high grade of FDG avid distal metastases in the nodal,lung,hepatic and bone are identified in the groups with elevation of both CEA/ CA153 and CA153 serum level only. Except, one patient with elevation of CA153 serum level only has negative FDG finding under prior history of skin metatasis and she is follow-up in clinic. For the patients with elevation of CEA level only, variable FDG PET/CT results are found. However, FDG PET/CT is still identified locoregional and distal bone metatasis in these two with higher CEA level, over 15 ng/L. In the lower CEA level group, second primary neoplasms as endometrial and gall bladder carcinoma are found by FDG PET/CT incidentally. The most patients with negative FDG finding in the group of lower elevation of CEA serum level are follow-up in clinic during the past six months. But, we still have one false negative case with multiple primary neoplasm, breast and colon cancer.

There is good correlation between increased tumor marker of CEA/CA153 serum level and FDG PET/CT finding for breast cancer patients in follow-up. And FDG PET/CT should become a pivot diagnosis to determinate following management.

FDG PET/CT, tumor marker, breast cancer.

Chen, Y, Hou, M, O-Yang, F, Liu, G, The Correlation between Increased Tumor Marker of CEA/ CA153 Serum Level and FDG PET/CT Finding for Breast Cancer Patients in Follow-up.  Radiological Society of North America 2006 Scientific Assembly and Annual Meeting, November 26 - December 1, 2006 ,Chicago IL. http://archive.rsna.org/2006/4435150.html